UKVIA Expresses Disappointment Over Welsh Tobacco Control Strategy

Aug.11.2022
UKVIA Expresses Disappointment Over Welsh Tobacco Control Strategy
The Welsh Tobacco Control Strategy lacks support for e-cigarettes and misses a significant opportunity for smoking cessation, says UKVIA.

The newly released Tobacco Control Strategy (TCS) in Wales has stated that it has not yet developed a position on e-cigarettes. The UKVIA has stated that, given the support of e-cigarettes in other parts of the UK, it will continue to engage with Welsh policymakers.


A plan to reduce smoking rates in Wales and achieve a "smoke-free" status by 2030 has been recently released. However, the plan has been criticized by the UK Vaping Industry Association (UKVIA) for lacking support for electronic cigarettes, which they describe as a missed opportunity. The UKVIA is the largest industry association representing the e-cigarette industry in the United Kingdom.


John Dunne, CEO of UKVIA stated, "While there are many commendable aspects to the strategy for reducing smoking rates in Wales, it is disappointing that the Welsh government hasn't gone further to seize this golden opportunity to embrace and advocate for e-cigarettes as the best and most effective way to help people quit smoking for good.


Although the Welsh TCS did mention e-cigarettes, it was only briefly noted that the Welsh government needs to develop its stance on e-cigarettes.


Dunne went on to say, "For this reason, we will continue to collaborate with the Welsh government, as in the recent example of the Khan review on smoking, which concluded that promoting e-cigarettes is absolutely crucial for achieving a smoke-free UK by 2030.


Welsh TCS has brought up the issue of preventing children and young people from smoking and using e-cigarettes - a topic that UKVIA has strongly advocated for. Dunne stated: "We welcome the Welsh government's plan to prevent young people from accessing e-cigarettes.


As an association, we have called on the UK government to impose stricter regulations on e-cigarette retailers who sell to young people. We recommend a fine of £10,000 for those caught in violation.


Returning to Wales, TCS lacks support for e-cigarettes as a tool to quit smoking. Dunne added, "There is indisputable evidence that e-cigarettes are effective in helping adults quit smoking. Support is growing among the scientific, academic, healthcare, and political communities, all of which now recognize e-cigarettes as an important component in helping smokers quit.


While it is disappointing to see that the Welsh government has not taken a more proactive stance on e-cigarettes, it is important to engage with politicians and decision-makers in the region to showcase the value of these devices and help the country achieve its smoke-free goals. Failing to do so could have serious consequences for Wales' ability to reduce smoking rates and minimize harm.


Meanwhile, in Scotland, a survey of 2,170 individuals found that 41% of respondents reported that e-cigarettes helped them quit smoking. The survey also found that only one-sixth of respondents wished for stricter regulations on e-cigarettes, while half hoped for more relaxed regulations. Scotland's government is currently considering whether to ban in-store promotions of e-cigarettes.


Statement:


This article is compiled from third-party information and is intended for industry professionals for educational and informational purposes only.


This article does not necessarily represent the views of 2FIRSTS, and 2FIRSTS cannot verify the truth or accuracy of the article's content. The translation of this article is intended only for internal industry discussion and research purposes.


Due to limitations in translation skills, the translated article may not accurately convey the original meaning. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in regard to any domestic, Hong Kong, Macao, Taiwan, or foreign statements and positions.


All compiled information is owned by the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Japan's Heated Tobacco Use Rises From 0.1% to 14.9% Over a Decade as Growth Extends Beyond Cigarette Switching
Japan's Heated Tobacco Use Rises From 0.1% to 14.9% Over a Decade as Growth Extends Beyond Cigarette Switching
A decade-long study published in The Lancet Regional Health – Western Pacific found that heated tobacco product use in Japan increased from 0.1% in 2015 to 14.9% in 2025, although growth slowed after 2018. Switching from conventional cigarettes remained an important source of HTP uptake, while the contribution from previously non-current users increased. Approximately 56% of HTP users also smoked conventional cigarettes in 2025. Separate industry data show that Japan's heated tobacco sales reached 73.4 billion units in fiscal 2025, approaching conventional cigarette sales of 78.2 billion units.
SCIENCE
Nov.10
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
During its coverage of Altria's booth at NACS Show 2026, 2Firsts documented product displays that prompted questions about U.S. tobacco advertising warning requirements. Following public comments from a former FDA official, 2Firsts sought responses from Altria and independently consulted U.S. regulatory lawyer Azim Chowdhury. Altria maintained that its B2B communications complied with applicable laws, while Chowdhury explained that federal warning rules provide no general trade-show exemption for e-cigarettes and nicotine pouches. The special report examines the broader regulatory implications.
Nov.04
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
A U.S. International Trade Commission (USITC) administrative law judge issued an initial determination on October 20, 2026, finding that certain Glas vaping devices, cartridges and components infringed 12 claims across two patents asserted by JUUL, constituting a violation of Section 337 of the Tariff Act of 1930. The judge recommended a limited exclusion order and a cease and desist order against the Glas respondents. Five months earlier, the FDA authorized four Glas e-cigarette pods, including mango, blueberry and two menthol variants. The patent investigation concerns device and cartridge structures and is separate from FDA premarket review. The proposed import restrictions have not become final, and their product-level scope remains unresolved.
company
Nov.05
DATA|UK Retail Research Group IGD Says Convenience Tobacco and Vape Sales Fell 10.6%, With 15.4% Market Share Versus Alcohol's 15.1%; Top Rank at Risk in 2027
DATA|UK Retail Research Group IGD Says Convenience Tobacco and Vape Sales Fell 10.6%, With 15.4% Market Share Versus Alcohol's 15.1%; Top Rank at Risk in 2027
Combined tobacco and vaping sales in UK convenience stores fell 10.6% year over year in the first half of 2026, making the category a major drag on channel performance, according to retail research organization IGD. Total convenience sales declined 1.2%, while sales excluding tobacco and vaping increased 0.7%. IGD's 2026 category-share figures show tobacco and vaping accounting for 15.4% of convenience sales, compared with 15.1% for alcohol. The organization forecasts alcohol could overtake tobacco and vaping as the largest category by sales value as early as 2027 if current trends continue. IGD expects the convenience market to increase from £48.6 billion in 2026 to £54.9 billion in 2031, a 2.5% compound annual growth rate, or 3.4% excluding tobacco and vaping.
DATA
Nov.11
Imperial Brands Plans to Cut Nearly 18% of Workforce as German Plant Closure and Polish Outsourcing Drive Restructuring
Imperial Brands Plans to Cut Nearly 18% of Workforce as German Plant Closure and Polish Outsourcing Drive Restructuring
Imperial Brands disclosed on November 17, 2026, that its global manufacturing and organisational restructuring is expected to reduce between 4,200 and 4,600 roles by the end of 2030, equivalent to approximately 16%–18% of its workforce at the end of 2025. The first phase covers 2,100 roles with departures confirmed or subject to consultation, while a further 2,100–2,500 positions are expected to be eliminated by 2030. The company is proceeding with the closure of its Langenhagen factory in Germany, has sold its manufacturing facility in Taiwan, and has transferred selected finance, procurement and supply-chain operations in Poland to Capgemini. The restructuring programme is expected to cost approximately £740 million, with Imperial targeting at least £320 million in annual cost savings by 2030.
company
Nov.18